Close Menu

personalized medicine

The xT platform integrates structured clinical patient data with results from a 648-gene DNA panel and whole-transcriptome RNA sequencing.

As adoption of personalized medicines has accelerated over the last four years, so has the number of marketed genetic and exome tests.

Reveal Genomics plans to have assays available within three years, and is eager to partner with pharmaceutical and diagnostics companies to fulfill its vision.

The company is employing Guardant360 in a Phase III trial assessing the efficacy of the drug both in a larger population and in women who test positive for ESR1 mutations.

Researchers concluded that there has been significant expansion of coverage for ctDNA assays over the past four years, but policies remain very heterogeneous and often limited.

The firm said the FDA clearance was supported by data across several lab sites and all variant classes in clinical samples from 35 tumor types.

A study of both tissue and blood samples from patients in a small trial found that liquid biopsy may detect putative resistance mutations missed in tissue.

The consortium aims to develop assays that can detect biomarkers of pulmonary fibrosis that can be used as early indicators of a treatment's activity.

The company is using the test to direct patient enrollment and treatment stratification in a trial of pembrolizumab (Keytruda) combination treatments.

The companies aim to develop technologies for interpreting cancer genome data, with a focus on linking genetic profiles with treatment responses.

Pages